Related references
Note: Only part of the references are listed.Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
Francesco Passamonti et al.
BLOOD (2014)
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Silvia Spoerl et al.
BLOOD (2014)
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
T. Zhou et al.
LEUKEMIA (2014)
Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
M. Massa et al.
LEUKEMIA (2014)
Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
Thorsten Hornung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
Annkristin Heine et al.
BLOOD (2013)
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2013)
EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry
Isabelle Cornez et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Inhibition of JAKs in Macrophages Increases Lipopolysaccharide-Induced Cytokine Production by Blocking IL-10-Mediated Feedback
Michael J. Pattison et al.
JOURNAL OF IMMUNOLOGY (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation
Jordan S. Fridman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2011)
Differentiation of Effector CD4 T Cell Populations
Jinfang Zhu et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt
Nicolas Manel et al.
NATURE IMMUNOLOGY (2008)
An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity1
Timothy J. Harris et al.
JOURNAL OF IMMUNOLOGY (2007)
JAK-STAT signaling: From interferons to cytokines
Christian Schindler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages
Lynn M. Williams et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
IL-2 receptor β-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells
Matthew A. Burchill et al.
JOURNAL OF IMMUNOLOGY (2007)
General nature of the STAT3-activated anti-inflammatory response
Karim C. El Kasmi et al.
JOURNAL OF IMMUNOLOGY (2006)
The V617F JAK2 mutation and the myeloproliferative disorders
MJ Percy et al.
HEMATOLOGICAL ONCOLOGY (2005)
Identification of an acquired JAK2 mutation in Polycythemia vera
RX Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R
C Parham et al.
JOURNAL OF IMMUNOLOGY (2002)
T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells
M Afkarian et al.
NATURE IMMUNOLOGY (2002)
Partial impairment of cytokine responses in Tyk2-deficient mice
M Karaghiosoff et al.
IMMUNITY (2000)
Medical progress: Myelofibrosis with myeloid metaplasia.
A Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
